Details of the Drug
General Information of Drug (ID: DMZ9L6Q)
| Drug Name |
3-((1H-imidazol-1-yl)methyl)aniline
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
3-(1H-imidazol-1-ylmethyl)aniline; 120107-85-9; 3-((1H-imidazol-1-yl)methyl)aniline; 3-(1-Imidazolylmethyl)aniline; 3-(imidazol-1-ylmethyl)aniline; Benzenamine, 3-(1H-imidazol-1-ylmethyl)-; 3-Imidazol-1-ylmethyl-phenylamine; Benzenamine,3-(1H-imidazol-1-ylmethyl)-; CHEMBL597369; 3-(imidazolylmethyl)phenylamine; 3-[(1H-Imidazol-1-yl)methyl]aniline; ACMC-20e0av; AC1Q51NE; 1-(3-aminobenzyl)imidazole; SCHEMBL860653; 3-(Imidazo-1-ylmethyl)aniline; AC1O5C89; CTK4B1687; DTXSID20424305; MolPort-000-143-257
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 173.21 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 0.9 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 2 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||


